SEC Company Response from ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858) (ACHV) — Jun 26, 2009

ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858)
Date: June 26, 2009 · CIK: 0000949858 · Accession: 0000950123-09-018121

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-160251

Date

June 26, 2009

Author

/s/ Randal R. Jones

Form

CORRESP

Company

ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858)

Letter

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Re: OncoGenex Pharmaceuticals — Registration Statement on Form S-3 (File No. 333-160251) filed on June 26, 2009

Dear Sir or Madam,

In connection with the Registration Statement on Form S-3 (file no. 333-160251) filed on June 26, 2009 by OncoGenex Pharmaceuticals, Inc., we are furnishing the correspondence attached as Exhibit A required under National Instrument 71-101.

Very truly yours,
/s/ Randal R. Jones

Show Raw Text

CORRESP
1
filename1.htm

Correspondence

RANDAL R. JONES

(206) 903-8814

FAX (206) 903-8820

JONES.RANDAL@DORSEY.COM

June 26, 2009

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7010

Re: OncoGenex Pharmaceuticals — Registration Statement on Form S-3 (File No. 333-160251)
filed on June 26, 2009

Dear Sir or Madam,

In connection with the Registration Statement on Form S-3 (file no. 333-160251) filed on June
26, 2009 by OncoGenex Pharmaceuticals, Inc., we are furnishing the correspondence attached as
Exhibit A required under National Instrument 71-101.

    Very truly yours,

    /s/ Randal R. Jones

    Randal R. Jones

EXHIBIT A

NOTICE OF FILING PURSUANT TO NATIONAL INSTRUMENT 71-101

The Multijurisdictional Disclosure System

    TO:

    British Columbia Securities Commission

    AND TO:

    The United States Securities and Exchange Commission

    RE:

    OncoGenex Pharmaceuticals, Inc. (the “Company”)

The Company has today filed a preliminary MJDS prospectus dated June 26, 2009, pursuant to National
Instrument 71-101, The Multijurisdictional Disclosure System (“NI 71-101”), and designates the
British Columbia as the principal jurisdiction in Canada.

DATED June 26, 2009.

ONCOGENEX PHARMACEUTICALS, INC.

    /s/ Scott Cormack

Scott Cormack

    President and Chief Executive Officer

SecProbe.io